Bispecific Intracellular Antibodies for Cell Penetration and Mdm2 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies face challenges in targeting intracellular sites due to the impermeability of cells to large molecules like proteins, leading to undesirable side effects with small molecule inhibitors, and the limited penetration of antibodies, which are specific but extracellular in nature.
Innovation Solution
Development of bispecific single-chain Fv fragments combining the cell-penetrating determinant of mAb 3E10 with intracellular target-binding determinants, such as anti-Mdm2, to transport antibodies into cells and regulate intracellular targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies are used to target intracellular sites, then binding specificity is improved, but cell penetration is worsened because cells are impervious to large molecules
Solution Approach 1:
The antibody is divided into a cell-penetrating portion (3E10 Fv fragment) and a target-binding portion (anti-Mdm2 Fv fragment). The cell-penetrating portion enables entry into the cell, while the target-binding portion maintains specific binding to the intracellular target Mdm2, thus resolving the contradiction between penetration and specificity.
Solution Approach 2:
The 3E10 Fv fragment acts as an intermediary that facilitates the entry of the antibody complex into the cell. It mediates the transport through the cell membrane by utilizing the hENT2 nucleoside salvage pathway, allowing the target-binding portion to reach its intracellular destination.
2Ease of operation
If small molecule inhibitors are used to target intracellular sites, then cell penetration is improved, but side effects are worsened due to binding unintended targets
Solution Approach 1:
The antibody is segmented into functional portions where the target-binding portion (anti-Mdm2 Fv fragment) provides high specificity for the intended target, preventing off-target binding and reducing side effects, while the cell-penetrating portion ensures adequate cell entry.
Solution Approach 2:
Different portions of the antibody have specialized functions: the 3E10 Fv fragment is optimized for cell penetration while the anti-Mdm2 Fv fragment is optimized for specific target binding. This local specialization allows each portion to excel at its designated task, minimizing harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for specific inhibition of intracellular targets, enhancing tumor suppression by increasing p53 levels and inhibiting cancer cell growth, with minimal toxicity and synergistic effects when combined with additional therapeutic agents.
Implementation Method 1
mAb 3E10 and its single-chain Fv fragment (scFv) are internalized through hENT2, an equilibrative nucleoside salvage pathway
Implementation Method 2
the second Fv fragment binds the intracellular target in the cell so that the bispecific antibody inhibits the intracellular target
Data Source
AI summary
The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.